These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22298228)

  • 1. Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.
    Batra AS; Alexander ME; Silka MJ
    Pediatr Cardiol; 2012 Mar; 33(3):394-401. PubMed ID: 22298228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC
    Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
    Olfson M; Huang C; Gerhard T; Winterstein AG; Crystal S; Allison PD; Marcus SC
    J Am Acad Child Adolesc Psychiatry; 2012 Feb; 51(2):147-56. PubMed ID: 22265361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
    Stiefel G; Besag FM
    Drug Saf; 2010 Oct; 33(10):821-42. PubMed ID: 20812768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of adult ADHD with stimulants.
    Spencer TJ
    CNS Spectr; 2007 Apr; 12(4 Suppl 6):8-11. PubMed ID: 17715564
    [No Abstract]   [Full Text] [Related]  

  • 6. Attention deficit hyperactivity disorder medications in children with heart disease.
    Berger S
    Curr Opin Pediatr; 2016 Oct; 28(5):607-12. PubMed ID: 27261563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder.
    Grcevich S; Rowane WA; Marcellino B; Sullivan-Hurst S
    J Child Adolesc Psychopharmacol; 2001; 11(1):35-41. PubMed ID: 11322743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor skills of children newly diagnosed with Attention Deficit Hyperactivity Disorder prior to and following treatment with stimulant medication.
    Brossard-Racine M; Shevell M; Snider L; Bélanger SA; Majnemer A
    Res Dev Disabil; 2012; 33(6):2080-7. PubMed ID: 22796639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of adult ADHD and comorbid disorders.
    Young JL
    CNS Spectr; 2006 Oct; 11(10 Suppl 11):10-2. PubMed ID: 17712918
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR; Skimming JW; Muniz R
    Clin Pediatr (Phila); 2010 Sep; 49(9):840-51. PubMed ID: 20693523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medications for adolescents with attention-deficit/hyperactivity disorder.
    Soileau EJ
    Adolesc Med State Art Rev; 2008 Aug; 19(2):254-67, viii-ix. PubMed ID: 18822831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing stimulant medication for attention-deficit/hyperactivity disorder.
    Wender EH
    Pediatr Rev; 2001 Jun; 22(6):183-90. PubMed ID: 11389305
    [No Abstract]   [Full Text] [Related]  

  • 19. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.